Evidence map›Paper›PMID 31694176›Full record

Observational studyNutrients2019

Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study.

Roberto Aquilani, Silvia Brugnatelli, Maurizia Dossena, Roberto Maestri, Sara Delfanti, Daniela Buonocore, Federica Boschi, Elena Simeti, Anna Maria Condino, Manuela Verri

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Roberto AquilaniDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Silvia BrugnatelliMedical Oncology Division, Fondazione IRCCS, Policlinico San Matteo, 27100 Pavia, Italy.
Maurizia DossenaDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Roberto MaestriDepartment of Biomedical Engineering of the Montescano Institute, Istituti Clinici Scientifici Maugeri IRCCS, 27040 Montescano (PV), Italy.
Sara DelfantiMedical Oncology Division, Fondazione IRCCS, Policlinico San Matteo, 27100 Pavia, Italy.
Daniela BuonocoreDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Federica BoschiDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
Elena SimetiDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Anna Maria CondinoDepartment of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
Manuela VerriDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
University of Pavia · ITIstituti Clinici Scientifici Maugeri · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITPoliclinico San Matteo Fondazione · IT

Funding

Fondazione IRCCS Policlinico San Matteo, Pavia, Italy Ricerca Corrente grant no. 08067611
6 · The paper itself

Abstract

Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress. We hypothesize that chemotherapy may worsen plasma amino acids (AAs) and markers of oxidative stress (MOS). Therefore, this study aimed to document plasma AAs and MOS before, during and after chemotherapy in colorectal cancer (CRC) surgery patients. Fourteen normal-weight CRC patients were enrolled one month after surgery and scheduled for oxaliplatin-fluoropyrimidine combination (XELOX) therapy. Venous blood samples for AA and MOS (malondialdehyde, MDA; 8-hydroxy-2'-deoxyguanosine, 8-OHdG) measurements were drawn in fasting patients before each oxaliplatin infusion at initiation (A), 1 month (B) and 3 months (C) of the therapy, and after XELOX had finished (6 months, D). The results showed that during XELOX therapy (from phase B to phase D), in comparison to baseline (phase A), the branched chain amino acid/essential amino acid ratio, branched chain amino acids expressed as a percentage of total AAs, and arginine expressed as a percentage of total AAs significantly decreased (

Indexed as

8-Hydroxy-2'-DeoxyguanosineAmino AcidsAntineoplastic Combined Chemotherapy ProtocolsArginineCapecitabineColectomyColorectal NeoplasmsFastingFemaleHumansLongitudinal StudiesMaleMalondialdehydeMiddle AgedOxaloacetatesOxidative Stress8-Hydroxy-2'-DeoxyguanosineAmino AcidsArginineCapecitabineMalondialdehydeOxaloacetateschemotherapycolorectal canceroxidative stressplasma amino acidssurgery

Identifiers

PMID31694176
PMCPMC6893861
OpenAlexW2987470752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.